Healthcare Finance News July 29, 2020
Many Pfizer/BioNTech sites are in diverse communities that have been disproportionately affected by COVID-19.
Several pharmaceutical and biotech companies are in the testing phase for a COVID-19 vaccine.
Pfizer and BioNTech said they have been chosen to lead the mRNA vaccine candidate against COVID-19. The vaccine consists of an mRNA strand that codes for a disease-specific antigen.
Assuming clinical success, Pfizer and BioNTech are on track to seek regulatory review as early as October and, if regulatory authorization is obtained, plan to supply up to 100 million doses by the end of this year and approximately 1.3 billion doses by the end of 2021, according to Pfizer.
Also this week, Moderna, a clinical stage biotechnology company, announced a Phase 3...
Today's Sponsors
Today's Sponsor